DE68926905D1 - Rezeptoren: ihre Identifizierung, Charakterisierung, Herstellung und Verwendung - Google Patents

Rezeptoren: ihre Identifizierung, Charakterisierung, Herstellung und Verwendung

Info

Publication number
DE68926905D1
DE68926905D1 DE68926905T DE68926905T DE68926905D1 DE 68926905 D1 DE68926905 D1 DE 68926905D1 DE 68926905 T DE68926905 T DE 68926905T DE 68926905 T DE68926905 T DE 68926905T DE 68926905 D1 DE68926905 D1 DE 68926905D1
Authority
DE
Germany
Prior art keywords
receptors
activation
transcription
disclosed
hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68926905T
Other languages
English (en)
Other versions
DE68926905T2 (de
Inventor
Ronald Mark Evans
Stanley Mark Hollenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salk Institute for Biological Studies
Original Assignee
Salk Institute for Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Institute for Biological Studies filed Critical Salk Institute for Biological Studies
Publication of DE68926905D1 publication Critical patent/DE68926905D1/de
Application granted granted Critical
Publication of DE68926905T2 publication Critical patent/DE68926905T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C07K2319/715—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16 containing a domain for ligand dependent transcriptional activation, e.g. containing a steroid receptor domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
DE68926905T 1988-11-30 1989-11-30 Rezeptoren: ihre Identifizierung, Charakterisierung, Herstellung und Verwendung Expired - Fee Related DE68926905T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/278,614 US5217867A (en) 1988-11-30 1988-11-30 Receptors: their identification, characterization, preparation and use

Publications (2)

Publication Number Publication Date
DE68926905D1 true DE68926905D1 (de) 1996-09-05
DE68926905T2 DE68926905T2 (de) 1997-01-02

Family

ID=23065666

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68926905T Expired - Fee Related DE68926905T2 (de) 1988-11-30 1989-11-30 Rezeptoren: ihre Identifizierung, Charakterisierung, Herstellung und Verwendung

Country Status (13)

Country Link
US (2) US5217867A (de)
EP (2) EP0371820B1 (de)
JP (1) JPH04501955A (de)
CN (1) CN1043741A (de)
AT (1) ATE140964T1 (de)
AU (1) AU635726B2 (de)
CA (1) CA2004339A1 (de)
DE (1) DE68926905T2 (de)
DK (1) DK102191D0 (de)
ES (1) ES2090041T3 (de)
GR (1) GR3020702T3 (de)
PT (1) PT92478B (de)
WO (1) WO1990006318A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) * 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
AU625534B2 (en) * 1987-11-25 1992-07-16 Immunex Corporation Interleukin-1 receptors
AU665039B2 (en) * 1987-12-02 1995-12-14 Salk Institute For Biological Studies, The Chimeric receptors and methods for identification
US5217867A (en) * 1988-11-30 1993-06-08 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
JPH04504654A (ja) * 1988-12-23 1992-08-20 ザ　ソーク　インスティテュート　フォア　バイオロジカル　スタディーズ レセプターの転写抑制活性組成物および方法
DE69132902D1 (de) * 1990-02-15 2002-02-21 Univ North Carolina Chapel Hill Methoden zur identifizierung heterofunktionaler fusionsproteine
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5747334A (en) * 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5688691A (en) * 1990-03-22 1997-11-18 The Salk Institute For Biological Studies Insect retinoid-like receptor compositions and methods
DE69132546T2 (de) 1990-09-13 2001-10-04 Univ Durham Expression von an g-protein gekoppelten rezeptoren in hefe
CA2098838C (en) * 1990-12-21 2002-11-26 Frances M. Sladek Liver enriched transcription factor
US20080139474A1 (en) * 1991-11-04 2008-06-12 David Israel Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
JP3504263B2 (ja) 1991-11-04 2004-03-08 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー 組み換え型骨形態形成蛋白ヘテロダイマー、組成物および使用法
US5756448A (en) * 1992-02-26 1998-05-26 The General Hospital Corporation Constitute activator of retinoid (CAR) receptor polypeptides
US6989242B1 (en) 1992-02-26 2006-01-24 The General Hospital Coporation Car receptors and related molecules and methods
DE69334150T2 (de) * 1992-05-14 2008-03-13 Baylor College Of Medicine, Houston Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie
US6416998B1 (en) 1992-09-02 2002-07-09 Baylor College Of Medicine Plasmid encoding a modified steroid hormone
WO1998018925A2 (en) * 1996-10-29 1998-05-07 Valentis, Inc. Modified glucocorticoid receptors, glucocorticoid receptors/progesterone receptors hybrids
IL110298A (en) * 1993-07-13 1999-04-11 Brann Mark Robert Identification of ligands by selective amplification of cells transfected with receptors
US6291206B1 (en) * 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
JP3717930B2 (ja) * 1993-12-07 2005-11-16 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー Ｂｍｐ−１２、ｂｍｐ−１３およびそれらの腱誘導組成物
US6518397B1 (en) 1997-07-24 2003-02-11 Shoukat Dedhar Pharmaceuticals for modulating hormone responsiveness
US5854202A (en) * 1995-01-24 1998-12-29 Dedhar; Shoukat Peptide fragments of calreticulin, peptide mimetics thereof, and pharmaceutical compostions comprising same
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7427492B1 (en) * 1995-06-05 2008-09-23 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor receptor-like2
WO1997004810A1 (en) 1995-07-28 1997-02-13 The Regents Of The University Of California Dax-1 protein, methods for production and use thereof
US6218128B1 (en) 1997-09-12 2001-04-17 Allergan Sales, Inc. Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
US6942980B1 (en) 1995-09-01 2005-09-13 Allergan, Inc. Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
US5958954A (en) * 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US6008204A (en) 1995-09-01 1999-12-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5952345A (en) * 1995-09-01 1999-09-14 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5776699A (en) * 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
KR100263137B1 (ko) * 1995-09-08 2000-08-01 오테스코그 페르 오판 수용체
US20030219832A1 (en) * 1996-03-11 2003-11-27 Klein Elliott S. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
CA2200423C (en) * 1996-03-26 2006-12-19 Sietse Mosselman Novel estrogen receptor
AU5729098A (en) * 1996-12-24 1998-07-17 Zymogenetics Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
US6037488A (en) 1997-04-19 2000-03-14 Allergan Sales, Inc. Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity
AU7383298A (en) * 1997-05-13 1998-12-08 Regents Of The University Of California, The Novel antiangiogenic peptide agents and their therapeutic and diagnostic use
WO1998054201A1 (en) * 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6222015B1 (en) 1997-09-08 2001-04-24 Merck & Co., Inc. Estrogen receptor
DE19750702A1 (de) * 1997-11-15 1999-05-27 Hoechst Marion Roussel De Gmbh Antisense Oligonucleotide gegen Tenascin zur Behandlung von Vitiligo
MXPA01002529A (es) 1998-09-10 2003-03-10 Pioneer Hi Bred Int Receptores de ecdisona y metodos para su uso.
US6727224B1 (en) * 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
US6586189B2 (en) 1999-06-18 2003-07-01 City Of Hope Screening method for PPAR-γ ligands
US6548739B2 (en) * 1999-06-18 2003-04-15 City Of Hope Method for activating peroxisome proliferator activated receptor-γ
US20050148018A1 (en) 1999-10-07 2005-07-07 David Weiner Methods of identifying inverse agonists of the serotonin 2A receptor
PT1223990E (pt) 1999-10-15 2004-12-31 Fidia Advanced Biopolymers Srl Formulacoes de acido hialuronico para administracao de proteinas osteogenicas
US7329728B1 (en) * 1999-10-25 2008-02-12 The Scripps Research Institute Ligand activated transcriptional regulator proteins
WO2001072837A2 (en) * 2000-03-24 2001-10-04 City Of Hope Methods of modulating drug clearance mechanisms by altering sxr activity
US20030082233A1 (en) * 2000-12-01 2003-05-01 Lyons Karen M. Method and composition for modulating bone growth
NZ530045A (en) * 2001-06-01 2007-07-27 Wyeth Corp Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
TWI267378B (en) * 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
EP1318400A1 (de) * 2001-12-06 2003-06-11 Unisensor S.A. Verfahren zur in vitro Diagnose auf der Basis von Gen-Regulation Mechanismen und entsprechendes Reagenz
EP1519744A4 (de) * 2002-05-17 2007-10-03 Wyeth Corp Injizierbare feste hyaluronsäureträger zur zuführung von osteogenen proteinen
US20050026949A1 (en) * 2003-07-30 2005-02-03 Allergan, Inc. Methods of therapeutic treatment using amounts of retinoids without regard to body weight
US20050027003A1 (en) * 2003-07-30 2005-02-03 Allergan, Inc. Methods of therapeutic treatment using retinoids with reduced side effects
US20050026950A1 (en) * 2003-07-30 2005-02-03 Allergan, Inc. Methods of therapeutic treatment using retinoids to achieve consistent bioavailability
JP5392981B2 (ja) * 2003-09-12 2014-01-22 ワイス・エルエルシー 骨形成蛋白の送達のための注入可能なリン酸カルシウム固体ロッドおよびペースト
EP1637885A1 (de) * 2004-09-16 2006-03-22 Vivalis Screeningverfahren von Konformation empfindlichen bindenden Peptiden
MX2007011591A (es) * 2005-03-30 2007-12-10 Wyeth Corp Metodo para estimular el crecimiento de cabello administrando bmps.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870009A (en) * 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4738922A (en) * 1984-05-25 1988-04-19 Dana Farber Cancer Institute Trans-acting transcriptional factors
US4761371A (en) * 1985-02-12 1988-08-02 Genentech, Inc. Insulin receptor
US4859609A (en) * 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US5171671A (en) * 1987-12-02 1992-12-15 The Salk Institute For Biological Studies Retinoic acid receptor composition
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5217867A (en) * 1988-11-30 1993-06-08 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use

Also Published As

Publication number Publication date
PT92478A (pt) 1990-05-31
WO1990006318A1 (en) 1990-06-14
US5217867A (en) 1993-06-08
CN1043741A (zh) 1990-07-11
AU4751290A (en) 1990-06-26
DK102191A (da) 1991-05-29
EP0371820B1 (de) 1996-07-31
DK102191D0 (da) 1991-05-29
DE68926905T2 (de) 1997-01-02
EP0371820A2 (de) 1990-06-06
ATE140964T1 (de) 1996-08-15
CA2004339A1 (en) 1990-05-31
EP0716145A1 (de) 1996-06-12
PT92478B (pt) 1995-07-18
AU635726B2 (en) 1993-04-01
JPH04501955A (ja) 1992-04-09
GR3020702T3 (en) 1996-11-30
EP0371820A3 (de) 1991-08-21
US5310662A (en) 1994-05-10
ES2090041T3 (es) 1996-10-16

Similar Documents

Publication Publication Date Title
DE68926905D1 (de) Rezeptoren: ihre Identifizierung, Charakterisierung, Herstellung und Verwendung
ATE139784T1 (de) Hybrid-rezeptoren, diese kodierende nukleinsäure, ihre herstellung und ihre verwendung zur bestimmung von liganden sowie deren antagonisten oder agonisten
DE68915958T2 (de) Verwendung angiostatischer Steroide zur Herstellung von Artzneimitteln zur Kontrolle von Augenhochdruck.
ATE299529T1 (de) Ptc gene und ihre verwendung
DE69007917T2 (de) Verfahren zum Mischen von Zement und Verstärkungsfasern und damit hergestellte Produkte.
DE3876534D1 (de) Verfahren zur herstellung von materialien auf basis von siliciumcarbid und eine zusammensetzung von rohmaterialien dafuer.
DE3586626D1 (de) Entwachsungskatalysatoren und -verfahren mit nichtzeolitischen molekularsieben.
ATE197068T1 (de) Toxoplasma gondii-antigene, ihre herstellung und ihre verwendung
DE3769326D1 (de) Verfahren und einrichtung zum erschmelzen von silikatischen rohstoffen, insbesondere zur herstellung von mineralwolle.
CA2207505A1 (en) Neurological drug screens
ATA294087A (de) Verfahren zur herstellung von 5,6-dihydroxyindol und dessen 3-alkylderivat, zwischenverbindungen und verwendung
ATE91976T1 (de) Aufzeichnungspapier und tintenstrahlaufzeichnungsverfahren unter verwendung dieses papiers.
DE59306475D1 (de) Verfahren zur Herstellung eines biologisch abbaubaren Verpackungsmittels und seine Verwendung
DE69002742T2 (de) Trennungsmaterial für Blutgerinnungsfaktoren, seine Herstellung und Verwendung.
ATE114155T1 (de) Verfahren zur herstellung von tigogenin-beta- cellobioside.
ATE23190T1 (de) Plasmid p svh 1 und seine verwendung.
DE59308947D1 (de) Reaktive, wasseremulgierbare Bindemittel und ihre Verwendung zur Herstellung von Lacken
DE59209970D1 (de) Verfahren zur Reinigung von Faktor XIII, monoklonale Antikörper gegen Faktor XIIIA, ihre Herstellung und Verwendung
DE68912100T4 (de) 4,4,5,8-Tetramethyl-1-oxaspiro(2.5)octan, Verfahren zu seiner Herstellung und seine Verwendung als Ausgangsprodukt in der Herstellung von 2,2,3,6-Tetramethyl-cyclohexan-carboxaldehyd.
DE59105781D1 (de) Verfahren zur Aufbereitung von Fasermaterial sowie Verwendung des Verfahrens.
ATA234989A (de) Bindemittel fuer wasserverduennbare beschichtungsmaterialien, vorwiegend fuer mineralische und bituminoese untergruende, und verfahren zur herstellung dieser bindemittel und deren verwendung
EP0446748A3 (de) Verwendung von Perylenfarbstoffen zur Herstellung von Schreib-, Druck- und Kopiererzeugnissen
DE59002266D1 (de) Verwendung von 4-(hydroxydi-phenylmethyl)-1-piperidyl-phenylalkan-derivaten zur herstellung eines antihistaminikums.
WIDAJ ON THE POSSIBILITY OF USING(WASTE) FILTRATION SILICA FOR THE PRODUCTION OF EARTHENWARE
Pirvu et al. The Texture of Grain Oriented Silicon Steel Strips in Different Phases of Technological Flow

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee